Previous close | 37.57 |
Open | 38.03 |
Bid | 38.47 x N/A |
Ask | 35.93 x N/A |
Day's range | 38.03 - 38.03 |
52-week range | 30.28 - 39.72 |
Volume | |
Avg. volume | 84 |
Market cap | 11.398B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | 21.01 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.19 (3.17%) |
Ex-dividend date | 17 May 2024 |
1y target est | N/A |
Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers. The company has in parallel launched the newest version of its home dialysis machine, the NxStage® Versi®HD with GuideMe Software, featuring enhancements designed to simplify treatment, increase ease of learning, and improv
"In the second quarter, we further improved our financial performance while executing against our strategic plan and the company transformation. This quarter is another important proof point for the operational turnaround as we remain focused to deliver on our targets", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "Our operating income margin progressed toward our 2025 margin target band, as Care Enablement increased its profitability. In Care Delivery, U.S. same market
Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emiss